ClinicalTrials.gg
Enrolling by invitationNCT06761066Updated Sep 1, 2026

Efficacy and Safety of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease

An interventional study of NVP-NK4146 and NVP-NK4146 Placebo in Alzheimer Disease, sponsored by NVP Healthcare. Enrolling by invitation at 1 site in South Korea. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by NVP Healthcare · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 174 studies in Alzheimer Disease with a site in Korea, Republic of — 34 open to participants now, 46 under way, 16 of them phase 3. Alzheimer Disease · Korea, Republic of.

Planned enrollment
119th of 157
60 · median 206
Started
2026
with 5 others
No phase
27 of 174
9 open now
Primary completion
2027-09
later than 22 of 45 live
Registered
152nd of 174
by date

Among the 174 studies in Alzheimer Disease with a site in Korea, Republic of, this one is the 119th largest by planned enrollment of the 157 interventional ones that give a count, is one of 6 that started in 2026, is one of 27 with no phase, reaches primary completion later than 22 of the 45 other live ones, and was the 152nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

34 of the 174 studies in Alzheimer Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Alzheimer Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to exploratively evaluate the efficacy and safety of NVP -NK4146 in improving mild cognitive impairment (MCI) in patients with due to Alzheimer's disease (AD) compared to placebo

Read the detailed description

36-week, single-center, randomized, double-blind, parallel-design, placebo-controlled trial

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female adults aged 60 or older
  2. Subject who meet the National Institute of Aging and Alzheimer's Associations (NIA-AA) core clinical criteria for MCI and have positive readings from amyloid PET
  3. Subject who can read and understand the Form and legends and who voluntarily decided to participate in current clinical trial and have signed the Informed Consent Form

Exclusion criteria

Exclusion Criteria:

  1. Subject diagnosed with dementia according to the criteria of or ICD-10
  2. Subject currently receiving treatment for malignant tumors (except those who have fully recovered from cancer for more than 5 years or those with basal cell carcinoma, squamous cell carcinoma, or prostate cancer may participate at the investigator's discretion)
  3. Subject who are illiterate and/or without any education
  4. Any other factors deemed by the investigator to be likely to ineligible for the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Active Group

    NVP-NK4146

    Dietary Supplement: NVP-NK4146

  • Placebo comparator
    Placebo Group

    NVP-NK4146 Placebo

    Dietary Supplement: NVP-NK4146 Placebo

Interventions

  • Dietary supplementNVP-NK4146

    BID for 36 weeks orally

  • Dietary supplementNVP-NK4146 Placebo

    BID for 36 weeks orally

06

What researchers measure

Primary outcomes

  1. amyloid PET scan

    Changes in brain amyloid measured by amyloid PET scan from baseline to 36 weeks

    Time frame: baseline and 36 weeks

Secondary outcomes

  1. ADAS-Cog(Alzheimer's Disease Assessment Scale-Cognitive Subscale)13

    Changes in ADAS-Cog 13 total score, memory score, and subscales from baseline to 36 weeks

    Time frame: baseline and 36 weeks

  2. CDR-SB(Clinical Dementia Rating-Sum of Boxes)

    Changes in CDR-SB(Clinical Dementia Rating-Sum of Boxes) and CDR total score from baseline to 36 weeks

    Time frame: baseline and 36 weeks

  3. GDS (Global Deterioration Scale)

    Change in GDS total score from baseline to 36 weeks

    Time frame: baseline and 36 weeks

  4. K-MMSE (the Korean Mini-Mental State Examination)

    Change in K-MMSE total score from baseline to 36 weeks

    Time frame: baseline and 36 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2027, 20 months after the start.

Of 77 industry-sponsored interventional studies with no phase under Alzheimer Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 20 months is above that.

Counting every sponsor, half of 963 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Jan 7, 2025
StartActual
Jan 20, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06761066
Lead sponsor
NVP Healthcare
Responsible party
Sponsor
First posted
Jan 7, 2025
Start date
Jan 20, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Sep 1, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion